JP2025186365A5 - - Google Patents
Info
- Publication number
- JP2025186365A5 JP2025186365A5 JP2025151922A JP2025151922A JP2025186365A5 JP 2025186365 A5 JP2025186365 A5 JP 2025186365A5 JP 2025151922 A JP2025151922 A JP 2025151922A JP 2025151922 A JP2025151922 A JP 2025151922A JP 2025186365 A5 JP2025186365 A5 JP 2025186365A5
- Authority
- JP
- Japan
- Prior art keywords
- pen
- peptides
- lys
- glu
- methylbenzoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959854P | 2020-01-10 | 2020-01-10 | |
| US62/959,854 | 2020-01-10 | ||
| JP2022542360A JP7744910B2 (ja) | 2020-01-10 | 2021-01-08 | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 |
| PCT/US2021/012842 WO2021142373A1 (en) | 2020-01-10 | 2021-01-08 | METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH α4β7 INTEGRIN ANTAGONISTS |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542360A Division JP7744910B2 (ja) | 2020-01-10 | 2021-01-08 | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025186365A JP2025186365A (ja) | 2025-12-23 |
| JP2025186365A5 true JP2025186365A5 (enExample) | 2026-05-11 |
Family
ID=76788328
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542360A Active JP7744910B2 (ja) | 2020-01-10 | 2021-01-08 | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 |
| JP2025151922A Pending JP2025186365A (ja) | 2020-01-10 | 2025-09-12 | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542360A Active JP7744910B2 (ja) | 2020-01-10 | 2021-01-08 | α４β７インテグリン拮抗薬で炎症性腸疾患を治療するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230063321A1 (enExample) |
| EP (1) | EP4093421A4 (enExample) |
| JP (2) | JP7744910B2 (enExample) |
| KR (1) | KR20220125268A (enExample) |
| AU (1) | AU2021205415B2 (enExample) |
| BR (1) | BR112022013628A2 (enExample) |
| CA (1) | CA3166637A1 (enExample) |
| IL (1) | IL294580A (enExample) |
| MX (1) | MX2022008486A (enExample) |
| PH (1) | PH12022551651A1 (enExample) |
| WO (1) | WO2021142373A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| CA3104418A1 (en) | 2018-07-12 | 2020-01-16 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| KR20250084325A (ko) * | 2023-12-01 | 2025-06-11 | 주식회사 쓰리빅스 | 염증성 장질환 예방 또는 치료용 약학 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013011130A (es) * | 2011-03-31 | 2013-10-30 | Genentech Inc | Metodos de administracion de antagonistas de integrina beta7. |
| WO2013078375A2 (en) * | 2011-11-23 | 2013-05-30 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
| US9273093B2 (en) * | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| CA2949215C (en) * | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| JP2017535527A (ja) * | 2014-10-01 | 2017-11-30 | プロタゴニスト セラピューティクス， インコーポレイテッド | 新規のα４β７ペプチド単量体及び二量体拮抗薬 |
| KR20200015540A (ko) * | 2017-05-10 | 2020-02-12 | 인사이클 세라퓨틱스, 인코포레이티드 | α4β7 인테그린을 타겟팅하는 호모데틱 사이클릭 펩타이드 |
-
2021
- 2021-01-08 EP EP21738981.6A patent/EP4093421A4/en active Pending
- 2021-01-08 JP JP2022542360A patent/JP7744910B2/ja active Active
- 2021-01-08 BR BR112022013628A patent/BR112022013628A2/pt not_active Application Discontinuation
- 2021-01-08 MX MX2022008486A patent/MX2022008486A/es unknown
- 2021-01-08 CA CA3166637A patent/CA3166637A1/en active Pending
- 2021-01-08 WO PCT/US2021/012842 patent/WO2021142373A1/en not_active Ceased
- 2021-01-08 PH PH1/2022/551651A patent/PH12022551651A1/en unknown
- 2021-01-08 AU AU2021205415A patent/AU2021205415B2/en active Active
- 2021-01-08 US US17/788,179 patent/US20230063321A1/en active Pending
- 2021-01-08 KR KR1020227025943A patent/KR20220125268A/ko not_active Withdrawn
-
2022
- 2022-07-07 IL IL294580A patent/IL294580A/en unknown
-
2025
- 2025-09-12 JP JP2025151922A patent/JP2025186365A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509790A5 (enExample) | ||
| EP0384362B1 (de) | Glycinderivate | |
| JP2005519041A5 (enExample) | ||
| JP2010529957A5 (enExample) | ||
| JP2017535527A5 (enExample) | ||
| JPH05506859A (ja) | 血液―脳関門透過性の増加方法 | |
| JP2004531516A (ja) | 新規ベンジリデンアミノグアニジンおよびそれらのメラノコルチンレセプターリガンドとしての使用方法 | |
| JP2016518351A5 (enExample) | ||
| RU2009110452A (ru) | Галеновые составы алискирена | |
| JP2023537921A5 (enExample) | ||
| JP3250804B2 (ja) | 治療用ペプチド | |
| US6489297B1 (en) | Vasoactive intestinal peptide analogs | |
| PT99940A (pt) | Processo de preparacao de ligandos hexa- e heptapeptidicos do receptor da anafilatoxina e de composicoes farmaceuticas | |
| CN1125451A (zh) | 生物活性加压素类似物 | |
| HU199879B (en) | Process for producing hexapeptides and pharmaceutical compositions comprising same as active ingredient | |
| AU765660B2 (en) | Ring modified cyclic peptide analogs | |
| JP2006523608A5 (enExample) | ||
| JP2021523945A5 (enExample) | ||
| CN101302246B (zh) | 黑色素皮质激素受体七肽类激动剂及其制备方法和用途 | |
| JP2021091728A5 (enExample) | ||
| JPS63303998A (ja) | 新規なａｎｆ誘導体 | |
| JP2006524183A5 (enExample) | ||
| JP2017500849A5 (enExample) | ||
| WO2002004016A1 (fr) | Preparations enteriques contenant des peptides physiologiquement actifs | |
| WO1995008341A1 (en) | Antifungal and anti-pneumocystis compounds, compositions containing such compounds, and methods of use |